BRPI0810179A2 - Composições de oligo-guluronato e galacturonato - Google Patents

Composições de oligo-guluronato e galacturonato

Info

Publication number
BRPI0810179A2
BRPI0810179A2 BRPI0810179-5A2A BRPI0810179A BRPI0810179A2 BR PI0810179 A2 BRPI0810179 A2 BR PI0810179A2 BR PI0810179 A BRPI0810179 A BR PI0810179A BR PI0810179 A2 BRPI0810179 A2 BR PI0810179A2
Authority
BR
Brazil
Prior art keywords
guluronate
galacturonate
oligo
compositions
Prior art date
Application number
BRPI0810179-5A2A
Other languages
English (en)
Inventor
Catherine Taylor
Kurt Ingar Draget
Olav Asmund Smidsrod
Original Assignee
Ntnu Technology Transfer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ntnu Technology Transfer As filed Critical Ntnu Technology Transfer As
Publication of BRPI0810179A2 publication Critical patent/BRPI0810179A2/pt
Publication of BRPI0810179B1 publication Critical patent/BRPI0810179B1/pt
Publication of BRPI0810179B8 publication Critical patent/BRPI0810179B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0810179A 2007-04-12 2008-04-11 composições de oligoguluronato e galacturonato e usos dos mesmos BRPI0810179B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0707096.4A GB0707096D0 (en) 2007-04-12 2007-04-12 Method
PCT/GB2008/001287 WO2008125828A2 (en) 2007-04-12 2008-04-11 Oligo-guluronate and galacturonate compositions

Publications (3)

Publication Number Publication Date
BRPI0810179A2 true BRPI0810179A2 (pt) 2014-12-30
BRPI0810179B1 BRPI0810179B1 (pt) 2019-12-10
BRPI0810179B8 BRPI0810179B8 (pt) 2021-05-25

Family

ID=38116633

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810179A BRPI0810179B8 (pt) 2007-04-12 2008-04-11 composições de oligoguluronato e galacturonato e usos dos mesmos

Country Status (14)

Country Link
US (1) US8841279B2 (pt)
EP (2) EP2155211B1 (pt)
JP (2) JP5649443B2 (pt)
KR (2) KR101336459B1 (pt)
CN (1) CN101711159B (pt)
AU (1) AU2008237710B2 (pt)
BR (1) BRPI0810179B8 (pt)
CA (2) CA2817754C (pt)
DK (2) DK2500025T3 (pt)
EA (1) EA018776B1 (pt)
ES (2) ES2553962T3 (pt)
GB (1) GB0707096D0 (pt)
MX (2) MX2009010889A (pt)
WO (1) WO2008125828A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2430881B (en) 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
KR101690631B1 (ko) 2007-11-27 2017-01-09 알지파마 아이피알 에이에스 바이오필름 퇴치에 있어서의 알기네이트 올리고머의 용도
GB0904941D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904942D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0909557D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Anti-microbial alginate oligomers
GB0909529D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Alginate oligomers for the inhibition of microbial adherence to surfaces
BRPI1011248A2 (pt) 2009-06-03 2016-03-22 Algipharma As métodos in vitro ou ex vivo de superação de resitência a pelo menos um antibiótico, para combate de contaminação de um sítio e melhora da eficácia de um antibiótico de macrolídeo para inibir o crescimento de bactéria mdr gram negativa, uso de um oligômero de alginato e produto
JO3676B1 (ar) * 2009-07-27 2020-08-27 Arc Medical Devices Inc مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
GB201116010D0 (en) 2011-09-15 2011-10-26 Algipharma As Use of alginate oligomers to enhance the effects of antifungal agents
GB201322777D0 (en) 2013-12-20 2014-02-05 Algipharma As Use of alginate oligomers as blood anticoagulants
MX2016008304A (es) * 2013-12-23 2017-01-09 Norwegian Univ Of Science And Tech Usos de oligouronatos en el tratamiento de cancer.
KR20160119259A (ko) * 2014-02-28 2016-10-12 알지파마 에이에스 낭포성 섬유증 및 cftr 이온 채널의 기능 결함과 관련된 기타 병태의 치료제로서 알기네이트 올리고머의 용도
FR3024358B1 (fr) * 2014-08-01 2017-11-10 Soc De Courtage Et De Diffusion Codif Int Compositions cosmetiques et complements alimentaires neuro-protecteurs comprenant de l'oligoalginate ayant un degre de polymerisation de 10 pour lutter contre le vieillissement de la peau.
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
GB201504878D0 (en) * 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
US11072668B2 (en) 2017-01-03 2021-07-27 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
JP7403152B2 (ja) 2017-03-28 2023-12-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解可能な抗菌性スキャフォールドとしての一酸化窒素放出性ポリアミノグリコシドおよびそれに関する方法背景
AU2018369760B2 (en) 2017-11-15 2025-01-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
WO2019173539A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
US20190298835A1 (en) 2018-03-29 2019-10-03 U.S. Army Research Laboratory Administration of tailored feedstock to increase antibiotic susceptibility
GB201812473D0 (en) 2018-07-31 2018-09-12 Algipharma As Method for the qualitative and quantitative detection of alginate oligomers in body fluids
JP7645546B2 (ja) 2018-12-28 2025-03-14 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 一酸化窒素放出抗菌性ポリマーおよびそれから製造された足場、ならびにそれに関する方法
US11684597B2 (en) 2019-01-28 2023-06-27 The United States Of America As Represented By The Secretary Of The Army Administration of tailored feedstock to increase nitro-containing amphenicol antibiotic susceptibility
GB201908639D0 (en) 2019-06-17 2019-07-31 Algipharma Ipr As Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2026008878A1 (en) 2024-07-04 2026-01-08 Algipharma As Antimycotic polyene-alginate oligomer conjugates

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297511A (pt) 1956-12-20
FR7576M (pt) 1968-03-27 1970-01-05
HU172831B (hu) * 1976-03-31 1978-12-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija kompleksov oligo- i poligalakturonnyk kislot s ionami zhiznenno vazhnykh metallov
JPS6176413A (ja) 1984-09-21 1986-04-18 Junzo Sunamoto 吸水性高分子によりカプセル化されたリポソ−ムの製造法
DD268865A1 (de) 1987-01-16 1989-06-14 Adw Ddr Verfahren zur herstellung eines pharmazeutischen praeparates
US4898852A (en) 1987-06-02 1990-02-06 Walsh William E Cyclopolgalcturonic acid composition and treatment
US4855128A (en) 1988-01-14 1989-08-08 Warner-Lambert Company Saccharide inhibition of dental plaque
JP2641472B2 (ja) 1988-01-30 1997-08-13 日本レダリー株式会社 感染症治療剤
EP0502949A4 (en) 1989-12-05 1993-02-24 Trancel Corporation Homologous guluronic acid alginate coating composition for in-vivo application and implantation and method of using same
US5459054A (en) * 1989-12-05 1995-10-17 Neocrin Company Cells encapsulated in alginate containing a high content of a- l- guluronic acid
AU7221691A (en) 1990-01-23 1991-08-21 Terje Espevik Mannuronic acid containing alginate wound healing composition and method
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5460957A (en) * 1992-04-28 1995-10-24 Maruha Corporation Calcium alginate oligosaccharide and method for producing the same from potassium or sodium alginate
HU213872B (en) 1993-09-08 1997-11-28 Mta Koezponti Kemiai Kutato In Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds
DE4330773A1 (de) * 1993-09-10 1995-03-16 Laevosan Gmbh & Co Kg Blockierung der Anlagerung von Keimen an menschliche Zellen
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
CA2235069C (en) * 1995-10-19 2010-12-14 Advanced Reproduction Technologies, Inc. Methods and compositions to improve germ cell and embryo survival and function
JP3512553B2 (ja) 1996-01-30 2004-03-29 ポーラ化成工業株式会社 便秘抑制剤及びそれを含有する組成物
FR2747045B1 (fr) 1996-04-05 1998-06-26 Hooreman Michel Nouveau medicament optimisant la viscosite des mucus et ameliorant le fonctionnement de l'intestin
NO305441B1 (no) * 1996-07-12 1999-05-31 Norsk Hydro As Anvendelse av G-blokk polysakkarider
EP0963196B1 (en) 1996-09-27 2005-01-19 Jagotec Ag Hyaluronic drug delivery system
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
NO305033B1 (no) * 1997-05-09 1999-03-22 Algipharma As Fremgangsmate for fremstilling av uronsyreblokker fra alginat
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
KR100219918B1 (ko) 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
JP3849144B2 (ja) * 1997-12-31 2006-11-22 ソニー株式会社 符号化データ出力装置及び方法並びに符号化データ制御装置及び方法
JP3932679B2 (ja) * 1998-07-21 2007-06-20 セイコーエプソン株式会社 ポリグルロン酸の製造法
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
WO2001015672A2 (en) 1999-08-26 2001-03-08 Governors Of The University Of Alberta Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
JP2001155905A (ja) * 1999-11-24 2001-06-08 Nec Corp 半導体装置およびトリミング方法ならびに記録媒体
US7785625B2 (en) * 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
KR100501584B1 (ko) * 2000-02-03 2005-07-18 (주)케이비피 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품
DE10006989A1 (de) * 2000-02-16 2001-08-23 Nutricia Nv Antiadhäsive Kohlenhydratmischung
PL202918B1 (pl) 2000-03-07 2009-08-31 Rush Presbyterian St Luke Przeciwbakteryjna i antykoncepcyjna kompozycja oraz jej zastosowanie
AU4445201A (en) 2000-03-30 2001-10-08 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
DE10019076A1 (de) * 2000-04-06 2001-10-18 Lang Christine Verwendung von Polygalakturoniden als Lebensmittelzusatzstoffe
JP2002338493A (ja) 2000-10-23 2002-11-27 Genaera Corp ムチン合成インヒビター
DE10057976B4 (de) 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Verfahren zur Herstellung von Pektinhydrolyseprodukten
US6440314B1 (en) * 2001-01-03 2002-08-27 Vulcan Chemical Technologies, Inc. Method for destroying chlorite in solution
ITMI20010347A1 (it) 2001-02-21 2002-08-21 Grisotech S A Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale
US6610331B1 (en) * 2002-05-30 2003-08-26 Scott M. Sweazy Fertility kit
JP2005145885A (ja) 2003-11-14 2005-06-09 Japan Science & Technology Agency アルギン酸オリゴマーからなる免疫機構賦活剤
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
JP4764426B2 (ja) * 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
JP2006028041A (ja) 2004-07-13 2006-02-02 Ltt Bio-Pharma Co Ltd 核酸含有ナノ粒子
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
US7621036B2 (en) 2005-06-21 2009-11-24 Cardiomems, Inc. Method of manufacturing implantable wireless sensor for in vivo pressure measurement
EP1745705A1 (en) 2005-07-20 2007-01-24 N.V. Nutricia Process for preparing uronic acid oligosaccharides by extrusion
GB2430881B (en) * 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
CA2625875C (en) 2005-10-21 2013-12-24 Living Cell Products Pty Limited Encapsulation system
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
US20110130444A1 (en) 2007-05-04 2011-06-02 Stefan Moisyadi Methods and compositions for targeted delivery of gene therapeutic vectors
CA2724408A1 (en) 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids

Also Published As

Publication number Publication date
KR101472245B1 (ko) 2014-12-11
EA200901299A1 (ru) 2010-06-30
BRPI0810179B8 (pt) 2021-05-25
US8841279B2 (en) 2014-09-23
WO2008125828A2 (en) 2008-10-23
MX2009010889A (es) 2009-10-28
JP5649443B2 (ja) 2015-01-07
AU2008237710B2 (en) 2014-02-06
KR101336459B1 (ko) 2013-12-04
JP2010523636A (ja) 2010-07-15
JP2014129401A (ja) 2014-07-10
DK2155211T3 (en) 2015-12-14
EP2500025B1 (en) 2017-10-18
WO2008125828A3 (en) 2009-06-04
CN101711159A (zh) 2010-05-19
CA2817754A1 (en) 2008-10-23
GB0707096D0 (en) 2007-05-23
AU2008237710A1 (en) 2008-10-23
CA2683914A1 (en) 2008-10-23
EP2155211B1 (en) 2015-08-26
EA018776B1 (ru) 2013-10-30
ES2655102T3 (es) 2018-02-16
EP2155211A2 (en) 2010-02-24
ES2553962T3 (es) 2015-12-15
KR20100016492A (ko) 2010-02-12
US20100152122A1 (en) 2010-06-17
CA2683914C (en) 2013-08-13
BRPI0810179B1 (pt) 2019-12-10
KR20130106446A (ko) 2013-09-27
DK2500025T3 (en) 2018-01-15
EP2500025A1 (en) 2012-09-19
CA2817754C (en) 2014-12-09
MX352972B (es) 2017-12-15
CN101711159B (zh) 2012-06-27

Similar Documents

Publication Publication Date Title
BRPI0810179A2 (pt) Composições de oligo-guluronato e galacturonato
LTPA2019003I1 (lt) Nauji junginiai ir kompozicijos ir jų panaudojimo būdai
BRPI0906980A2 (pt) Composição de derivados e maleatados
EP2515946A4 (en) NANOCONJUGATE AND NANOCONJUGATE FORMULATIONS
EP2167043A4 (en) NEW USE CO-CRYSTAL COMPOSITIONS
PL3812360T3 (pl) Związki monochlorotrifluoropropenu oraz kompozycje i sposoby ich zastosowania
PT2424372T (pt) Composições antimicrobianas e métodos de uso relacionados
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
PL2214679T3 (pl) Kompozycje kortykosteroidów
BR112012005237A2 (pt) utilização de composições ternárias
BRPI1011587A2 (pt) compostos e composições terapèuticas
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
EP2136768A4 (en) Structured surfactant compositions
DK2011486T3 (da) Farmaceutiske sammensætninger af rifaximin
EP2124523A4 (en) BREEDING LINE P2428-5006090
PT2161038E (pt) Composições e suas utilizações dirigidas à huntingtina
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
PT2356462T (pt) Composições e métodos anti-cxcr1
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
CR10562A (es) Nuevos derivados de piridazina
DK2111555T3 (da) Diagnosticering af præeklampsi
BRPI0819449A2 (pt) Composições cosméticas de multietapas
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
BRPI0813681A2 (pt) Detecção de coproantígeno de nematelminto
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: NTNU TECHNOLOGY TRANSFER AS (NO)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2770 DE 06-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.